Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 29 (10). S. 2062 - 2069. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n = 54, all grades III or IV) or SR-cGVHD (n = 41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1-7) and SR-cGVHD (1-10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3-90.7%, 95% confidence interval (CI)) and 97.4% (92.3-100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Zeiser, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Burchert, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lengerke, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Verbeek, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maas-Bauer, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzelder, S. K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spoerl, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ditschkowski, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ecsedi, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sockel, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ayuk, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ajib, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Fontbrune, F. S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Na, I-KUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Penter, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Holtick, U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuler, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meyer, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Apostolova, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bertz, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Marks, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Luebbert, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waesch, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stoelzel, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ordemann, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bug, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobbe, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Negrin, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brune, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spyridonidis, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmitt-Graeff, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van der Velden, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huls, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mielke, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grigoleit, G. U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuball, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Flynn, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ihorst, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Du, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blazar, B. R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arnold, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroeger, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Passweg, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Halter, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Socie, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beelen, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peschel, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neubauer, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finke, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duyster, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Bubnoff, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-392167
DOI: 10.1038/leu.2015.212
Journal or Publication Title: Leukemia
Volume: 29
Number: 10
Page Range: S. 2062 - 2069
Date: 2015
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ANTITHYMOCYTE GLOBULIN THERAPY; ACUTE GVHD; EXTRACORPOREAL PHOTOPHERESIS; MYCOPHENOLATE-MOFETIL; CYTOKINE INHIBITION; FACTOR-RECEPTOR; RESISTANT; MARROW; TOFACITINIB; COMBINATIONMultiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/39216

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item